CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company’s disciplined, opportunistic, and flexible approach to capital deployment.
The Company’s digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pillar of the program, the addition of Bitcoin represents a strategic evolution intended to broaden exposure across established digital assets.
Cosmos Health is also selectively evaluating the inclusion of additional cryptocurrencies within this framework, based on market conditions and alignment with the Company’s broader financial strategy. This expanded approach enhances the Company’s flexibility to respond to changing market dynamics, supports diversification, and enables the pursuit of opportunities consistent with its long-term financial objectives and shareholder interests, including, as previously disclosed, exploring potential opportunities related to the tokenization of high-value intellectual property.
To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, reflecting the combined value of its Ethereum holdings and the newly completed Bitcoin investment.
Greg Siokas, CEO of Cosmos Health, stated: “Our digital assets strategy is designed to be adaptive, disciplined, and opportunistic. The decision to invest in Bitcoin, executed at an average price below $70,000 per Bitcoin, reflects our view that deploying capital during periods of intense market sell-offs can create value over time. While Ethereum remains a key pillar of our digital assets program, we believe that adding Bitcoin, along with the potential inclusion of other select cryptocurrencies, enhances diversification and strengthens our overall capital deployment strategy.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
